Related Experiment Video

Updated: May 28, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds

F A Syed1, J H N Bett, D L Walters

  • 1The Prince Charles Hospital, Brisbane, Queensland, Australia. sfarhan5@yahoo.com.

Cardiovascular & Hematological Disorders Drug Targets
|November 3, 2011
PubMed

Insights

Dual anti-platelet therapy with aspirin and clopidogrel is standard for acute coronary syndromes (ACS). New anti-platelet agents are being evaluated to improve outcomes beyond current therapies for ACS patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel is a standard treatment for acute coronary syndromes (ACS).
  • Despite DAPT's efficacy, many ACS patients experience recurrent ischemic events.
  • Limitations of clopidogrel include delayed onset, variable response, and lack of an intravenous form.

Purpose of the Study:

  • To review existing anti-platelet regimens for ACS.
  • To discuss novel anti-platelet agents under clinical evaluation for ACS management.

Main Methods:

  • Literature review of randomized controlled trials on anti-platelet therapy in ACS.
  • Discussion of the pharmacological properties and clinical limitations of aspirin and clopidogrel.
  • Overview of emerging anti-platelet agents and their clinical trial status.

Main Results:

  • Aspirin and clopidogrel significantly reduce cardiovascular events in ACS patients.
  • Aspirin is a weak anti-platelet agent, and clopidogrel's effectiveness is limited by its prodrug nature and inter-individual variability.
  • Novel anti-platelet agents aim to overcome the shortcomings of current therapies.

Conclusions:

  • Novel anti-platelet agents show promise in addressing the unmet needs in ACS management.
  • Further clinical evaluation is necessary to establish the role of new agents in ACS treatment paradigms.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...